Aromatase, a cytochrome P-450 enzyme that catalyzes the conversion of androgens to estrogens, is the major mechanism of estrogen synthesis in the post-menopausal woman. We review some of the recent scientific advances which shed light on the biologic significance, physiology, expression and regulation of aromatase in breast tissue. Inhibition of aromatase, the terminal step in estrogen biosynthesis, provides a way of treating hormone-dependent breast cancer in older patients. Aminoglutethimide was the first widely used aromatase inhibitor but had several clinical drawbacks. Newer agents are considerably more selective, more potent, less toxic and easier to use in the clinical setting. This article reviews the clinical data supporting the use of the potent, oral competitive aromatase inhibitors anastrozole, letrozole and vorozole and the irreversible inhibitors 4-OH androstenedione and exemestane. The more potent compounds inhibit both peripheral and intra-tumoral aromatase. We discuss the evidence supporting the notion that aromatase inhibitors lack cross-resistance with antiestrogens and suggest that the newer, more potent compounds may have a particular application in breast cancer treatment in a setting of adaptive hypersensitivity to estrogens. Currently available aromatase inhibitors are safe and effective in the management of hormone-dependent breast cancer in post-menopausal women failing antiestrogen therapy and should now be used before progestational agents. There is abundant evidence to support testing these compounds as first-line hormonal therapy for metastatic breast cancer as well as part of adjuvant regimens in older patients and quite possibly in chemoprevention trials of breast cancer.

This article has been cited by other articles:

				C. Chargari, L. Vedrine, O. Bauduceau, S. Le Moulec, B. Ceccaldi, and N. Magne Reapprasial of the role of endocrine therapy in meningioma management Endocr. Relat. Cancer, December 1, 2008; 15(4): 931 - 941. [Abstract] [Full Text] [PDF]

				J. Jiang, N. Sarwar, D. Peston, E. Kulinskaya, S. Shousha, R. C. Coombes, and S. Ali Phosphorylation of Estrogen Receptor-{alpha} at Ser167 Is Indicative of Longer Disease-Free and Overall Survival in Breast Cancer Patients Clin. Cancer Res., October 1, 2007; 13(19): 5769 - 5776. [Abstract] [Full Text] [PDF]

				R. Lupu and J. A. Menendez Targeting Fatty Acid Synthase in Breast and Endometrial Cancer: An Alternative to Selective Estrogen Receptor Modulators? Endocrinology, September 1, 2006; 147(9): 4056 - 4066. [Abstract] [Full Text] [PDF]

				A.-M. Cleton-Jansen, H. M. van Beerendonk, H. J. Baelde, J. V.G.M. Bovee, M. Karperien, and P. C.W. Hogendoorn Estrogen Signaling Is Active in Cartilaginous Tumors: Implications for Antiestrogen Therapy as Treatment Option of Metastasized or Irresectable Chondrosarcoma Clin. Cancer Res., November 15, 2005; 11(22): 8028 - 8035. [Abstract] [Full Text] [PDF]

				R. W. Brueggemeier, J. C. Hackett, and E. S. Diaz-Cruz Aromatase Inhibitors in the Treatment of Breast Cancer Endocr. Rev., May 1, 2005; 26(3): 331 - 345. [Abstract] [Full Text] [PDF]

				B. K. Dunn, D. L. Wickerham, and L. G. Ford Prevention of Hormone-Related Cancers: Breast Cancer J. Clin. Oncol., January 10, 2005; 23(2): 357 - 367. [Abstract] [Full Text] [PDF]

				S. J. Ellem, J. F. Schmitt, J. S. Pedersen, M. Frydenberg, and G. P. Risbridger Local Aromatase Expression in Human Prostate Is Altered in Malignancy J. Clin. Endocrinol. Metab., May 1, 2004; 89(5): 2434 - 2441. [Abstract] [Full Text] [PDF]

				S. Soysal, M. E. Soysal, S. Ozer, N. Gul, and T. Gezgin The effects of post-surgical administration of goserelin plus anastrozole compared to goserelin alone in patients with severe endometriosis: a prospective randomized trial Hum. Reprod., January 1, 2004; 19(1): 160 - 167. [Abstract] [Full Text] [PDF]

				R. J. Santen, R. X. Song, Z. Zhang, W. Yue, and R. Kumar Adaptive Hypersensitivity to Estrogen: Mechanism for Sequential Responses to Hormonal Therapy in Breast Cancer Clin. Cancer Res., January 1, 2004; 10(1): 337S - 345S. [Abstract] [Full Text] [PDF]

				L. C. Ciobanu, V. Luu-The, C. Martel, F. Labrie, and D. Poirier Inhibition of Estrone Sulfate-induced Uterine Growth by Potent Nonestrogenic Steroidal Inhibitors of Steroid Sulfatase Cancer Res., October 1, 2003; 63(19): 6442 - 6446. [Abstract] [Full Text] [PDF]

				T. Suzuki, T. Nakata, Y. Miki, C. Kaneko, T. Moriya, T. Ishida, S. Akinaga, H. Hirakawa, M. Kimura, and H. Sasano Estrogen Sulfotransferase and Steroid Sulfatase in Human Breast Carcinoma Cancer Res., June 1, 2003; 63(11): 2762 - 2770. [Abstract] [Full Text] [PDF]

				H. Mouridsen, M. Gershanovich, Y. Sun, R. Perez-Carrion, C. Boni, A. Monnier, J. Apffelstaedt, R. Smith, H. P. Sleeboom, F. Jaenicke, et al. Phase III Study of Letrozole Versus Tamoxifen as First-Line Therapy of Advanced Breast Cancer in Postmenopausal Women: Analysis of Survival and Update of Efficacy From the International Letrozole Breast Cancer Group J. Clin. Oncol., June 1, 2003; 21(11): 2101 - 2109. [Abstract] [Full Text] [PDF]

				S. Sebastian, K. Takayama, M. Shozu, and S. E. Bulun Cloning and Characterization of a Novel Endothelial Promoter of the Human CYP19 (Aromatase P450) Gene that Is Up-Regulated in Breast Cancer Tissue Mol. Endocrinol., October 1, 2002; 16(10): 2243 - 2254. [Abstract] [Full Text] [PDF]

				A. Conley, S. Mapes, C. J. Corbin, D. Greger, and S. Graham Structural Determinants of Aromatase Cytochrome P450 Inhibition in Substrate Recognition Site-1 Mol. Endocrinol., July 1, 2002; 16(7): 1456 - 1468. [Abstract] [Full Text] [PDF]

				M. Shozu, H. Sumitani, T. Segawa, H.-J. Yang, K. Murakami, T. Kasai, and M. Inoue Overexpression of Aromatase P450 in Leiomyoma Tissue Is Driven Primarily through Promoter I.4 of the Aromatase P450 Gene (CYP19) J. Clin. Endocrinol. Metab., June 1, 2002; 87(6): 2540 - 2548. [Abstract] [Full Text] [PDF]

				G. Thordarson, A. V. Lee, M. McCarty, K. Van Horn, O. Chu, Y.-C. Chou, J. Yang, R. C. Guzman, S. Nandi, and F. Talamantes Growth and characterization of N-methyl-N-nitrosourea-induced mammary tumors in intact and ovariectomized rats Carcinogenesis, December 1, 2001; 22(12): 2039 - 2047. [Abstract] [Full Text] [PDF]

				M. H. Cohen, S. Hirschfeld, S. F. Honig, A. Ibrahim, J. R. Johnson, J. J. O'Leary, R. M. White, G. A. Williams, and R. Pazdur Drug Approval Summaries: Arsenic Trioxide, Tamoxifen Citrate, Anastrazole, Paclitaxel, Bexarotene Oncologist, February 1, 2001; 6(1): 4 - 11. [Abstract] [Full Text]